このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Esperion Therapeutics 配当金

配当金基準チェック /06

Esperion Therapeutics配当金を支払った記録がありません。

主要情報

n/a

配当利回り

n/a

配当性向

業界平均利回り	2.2%
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
一株当たり利益	-US$0.46
3年後の配当利回り予想	0%

最近の配当金アップデート

更新なし

Recent updates

Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock

May 20

A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics

Feb 28

Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations

Jan 22

Esperion Is Sitting On A Potential Blockbuster Drug

Jan 14

Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Jun 19

Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Mar 09

Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Feb 23

Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol

Aug 26

Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings

Aug 09

Esperion Therapeutics Q2 2022 Earnings Preview

Aug 01

Esperion Therapeutics: 2021 Labors Paying Off In 2022

May 07

Esperion Therapeutics: Ready For Growth Ahead Of Clear Outcomes Topline Data Readout

Feb 24

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Analysts Are Reducing Their Forecasts For This Year

May 09

Esperion Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 04

決済の安定と成長

配当データの取得

安定した配当: ESPRの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: ESPRの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Esperion Therapeutics 配当利回り対市場

ESPR 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (ESPR)	n/a
市場下位25% (US)	1.5%
市場トップ25% (US)	4.7%
業界平均 (Pharmaceuticals)	2.2%
3年後のアナリスト予想 (ESPR)	0%

注目すべき配当: ESPRは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: ESPRは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: ESPRの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: ESPRが配当金を報告していないため、配当金の持続可能性を計算できません。

Esperion Therapeutics 配当金

配当金 基準チェック /06

主要情報

最近の配当金アップデート

Recent updates

Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock

First quarter 2024 earnings released: EPS: US$0.36 (vs US$0.79 loss in 1Q 2023)

Esperion Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Esperion Therapeutics, Inc., Annual General Meeting, May 23, 2024

Consensus EPS estimates upgraded to US$0.37 loss

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Consensus revenue estimates fall by 12%

Price target decreased by 13% to US$7.41

A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Esperion Therapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations

Esperion Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $85.05 million.

Esperion Is Sitting On A Potential Blockbuster Drug

Forecast breakeven date pushed back to 2025

U.S. FDA Updates LDL-C Lowering Indication for Esperion's NEXLETOL®? (bempedoic Acid) Tablet and NEXLIZET®? (bempedOic Acid and ezetimibe) Tablet

New major risk - Shareholder dilution

Partners Announce Transform Trial to Evaluate Personalized Heart Disease Care Strategies At American Heart Association 2023

Price target decreased by 18% to US$9.14

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Esperion Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Market cap size

Consensus EPS estimates upgraded to US$1.99 loss

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Esperion Therapeutics, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet

Esperion Therapeutics, Inc. Announces the Results from its Pre-Specified, Primary Prevention Clear Outcomes Subgroup Analysis

Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Forecast breakeven date moved forward to 2024

Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment At Endo 2023

Esperion Announces Submission of Supplemental New Drug Applications to U.S. Fda for Nexletol(R) (Bempedoic Acid) Tablet and Nexlizet(R) (Bempedoic Acid and Ezetimibe) Tablet

Price target decreased by 10% to US$10.08

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 12% to US$12.22

Price target decreased by 11% to US$10.41

Consensus revenue estimates fall by 24%

Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Consensus revenue estimates increase by 22%

Consensus revenue estimates fall by 20%

Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Esperion Therapeutics, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Forecast to breakeven in 2024

Esperion Therapeutics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2022

Esperion Therapeutics, Inc. Announces CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology

Esperion Therapeutics, Inc. Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint

Esperion Therapeutics, Inc. Appoints Ben Halladay as Chief Financial Officer

High number of new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$12.10

Esperion Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Esperion Announces Bempedoic Acid NEXLETOL Recommends as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway

Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol

Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Esperion Therapeutics Q2 2022 Earnings Preview

Esperion Therapeutics, Inc. to Report Q2, 2022 Results on Aug 02, 2022

High number of new directors

Esperion Appoints J. Martin Carroll to Its Board of Directors

High number of new directors

Esperion Therapeutics: 2021 Labors Paying Off In 2022

Price target increased to US$11.67

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

High number of new directors

Esperion Therapeutics, Inc. to Report Q1, 2022 Results on May 03, 2022

Esperion Therapeutics, Inc., Annual General Meeting, May 26, 2022

Esperion Therapeutics, Inc. Announces Appointment of Eric Warren, R.Ph. as Chief Commercial Officer

Full year 2021 earnings: EPS misses analyst expectations

Esperion Therapeutics: Ready For Growth Ahead Of Clear Outcomes Topline Data Readout

Price target decreased to US$9.15

Esperion Therapeutics, Inc. to Report Q4, 2021 Results on Feb 22, 2022

配当金基準チェック /06